Buprenorphine Treatment for Probationers and Parolees

REFERENCES

• Glaze LP, Bonczar TP. Probation and Parole in the United States, 2010. Washington, DC: United States Department of Justice, Bureau of Justice Statistics; 2011. Bulletin: NCJ 236019.
   Google Scholar
• Schmalleger F. Criminal Justice Today: An Introductory Text for the 21st Century. 10th ed. Upper Saddle River, NJ: Pearson Prentice Hall; 2010.
   Google Scholar
• Cropsey KL, Lane PS, Hale GJ, et al. Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug Alcohol Depend. 2011;119:172–178.
   PubMed Web of Science ®Google Scholar
• Lee JD, Grossman E, Truncali A, et al. Buprenorphine-naloxone maintenance following release from jail. Subst Abus. 2012;33:40–47.
   PubMed Web of Science ®Google Scholar
• Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99:222–230.
   PubMed Web of Science ®Google Scholar
• Inciardi JA. The War on Drugs IV. Upper Saddle River, NJ: Prentice Hall; 2008.
   Google Scholar
• Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Mental and substance use disorders among adult men on probation or parole: some success against a persistent problem. http://oas.samhsa.gov/2k11/NIJ_Data_Review/MentalDisorders.htm. Published 2011. Accessed July 1, 2013.
   Google Scholar
• Office of National Drug Control Policy. National Drug Control Strategy—2009 Annual Report. Washington, DC: Author; 2009.
   Google Scholar
• Friedmann PD, Hoskinson R, Gordon M, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33:9–18.
   PubMed Web of Science ®Google Scholar
• Coviello DM, Cornish JW, Lynch KG, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33:48–59.
   PubMed Web of Science ®Google Scholar
• Guydish J, Chan M, Bostrom A, Jessup M, Davis T, Marsh C. A randomized trial of probation case management for drug-involved women offenders. Crime Delinq. 2011;57:167–198.
   PubMed Web of Science ®Google Scholar
• Anglin MD. Pretreatment characteristics and treatment performance of legally coerced versus voluntary methadone maintenance admissions. Criminology. 1989;27:537–557.
   Web of Science ®Google Scholar
• Desmond DP, Maddux JF. Compulsory supervision and methadone maintenance. J Subst Abuse Treat. 1996;13:79–83.
   PubMed Web of Science ®Google Scholar
• Grella CE, Anglin MD, Wugalter SE, Rawson R, Hasson A. Reasons for discharge from methadone maintenance for addicts at high risk of HIV infection or transmission. J Psychoactive Drugs. 1994;26:223–232.
   PubMed Web of Science ®Google Scholar
• Joe GW, Simpson DD, Broome KM. Effects of readiness for drug abuse treatment on client retention and assessment of process. Addiction. 1998;93:1177–1190.
   PubMed Web of Science ®Google Scholar
• Kelly SM, O’Grady KE, Jaffe JH, Gandhi D, Schwartz RP. Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment. J Addict Med. 2013;7:133–138.
   PubMed Web of Science ®Google Scholar
• Simpson DD, Friend HJ. Legal status and long-term outcomes for addicts in the DARP follow-up project. In: Leukefeld C, Tims F, eds. Compulsory Treatment of Drug Abuse: Research and Clinical Practice. NIDA Research Monograph Series #86. Washington, DC: Government Printing Office; 1988:81–89.
   Google Scholar
• Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1997;14:529–534.
   PubMed Web of Science ®Google Scholar
• Coviello DM, Cornish JW, Lynch KG, Alterman AI, O’Brien CP. A randomized trial of oral naltrexone for treating opioid-dependent offenders. Am J Addict. 2010;19:422–432.
   PubMed Web of Science ®Google Scholar
• Wang EA, Moore BA, Sullivan LE, Fiellin DA. Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. J Gen Intern Med. 2010;25:670–674.
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, Jaffe JH. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend. 2013;128:222–229.
   PubMed Web of Science ®Google Scholar
• Abdel-Salam S, Albizu-Garcia C, Ducharme LJ, et al. A cluster randomized trial of an organizational linkage intervention for offenders with substance abuse disorders: study protocol. The MATICCE Workgroup of the CJ-DATS Cooperative. Health Justice. 2013. http://www.healthandjusticejournal.com/content/1/1/6. Accessed December 19, 2014.
   PubMedGoogle Scholar
• McLellan AT, Alterman AI, Cacciola J, Metzger D, O’Brien CP. A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis. 1992;180:101–110.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–1342.
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91:220–227.
   PubMed Web of Science ®Google Scholar
• Nurco DN, Balter MB, Kinlock TW. Vulnerability to narcotic addiction: preliminary findings. J Drug Issues. 1994;24:292–313.
   Web of Science ®Google Scholar
• Nurco DN, Hanlon TE, O’Grady KE, Kinlock TW. The early emergence of narcotic addict types. Am J Drug Alcohol Abuse. 1997;23:523–542.
   PubMed Web of Science ®Google Scholar
• Greenfield SF, Beck SE, Lawson K, Brady KT. Women and addiction. In: Ruiz P, Strain EC, eds. Substance Abuse: A Comprehensive Textbook. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:847–870.
   Google Scholar
• Epstein DH, Phillips KA, Preston KL. Opioids. In: Ruiz P, Strain EC, eds. Substance Abuse: A Comprehensive Textbook. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:161–190.
   Google Scholar
• Scott CK, Dennis ML. The first 90 days following release from jail: findings from the Recovery Management Checkups for Women Offenders (RMCWO) experiment. Drug Alcohol Depend. 2012;125:110–118.
   PubMed Web of Science ®Google Scholar
• Zanis DA, Coviello DM, Lloyd JJ, Nazar BL. Predictors of drug treatment completion among parole violators. J Psychoactive Drugs. 2009;41:173–180.
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT. Developing and Implementing a new prison-based buprenorphine treatment program. J Offender Rehabil. 2010;49:91–109.
   PubMedGoogle Scholar
• Gordon MS, Kinlock TW, Miller PM. Medication-assisted treatment research with criminal justice populations: challenges of implementation. Behav Sci Law. 2011;29:829–845.
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171:425–431.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Weiss L, Botsko M, et al. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S33–S38.
   PubMedGoogle Scholar
• Kinlock TW, Gordon MS, Schwartz RP. Incarcerated populations. In: Ruiz P, Strain E, eds. Lowinson & Ruiz's Substance Abuse: A Comprehensive Textbook. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:881–891.
   Google Scholar
• Nurco DN. A long-term program of research on drug use and crime. Subst Use Misuse. 1998;33:1817–1837.
   PubMed Web of Science ®Google Scholar
• Lilly JR, Cullen FT, Ball RA. Criminological Theory: Context and Consequences. Thousand Oaks, CA: Sage Publications; 2011.
   Google Scholar
• Wilson JQ, Herrnstein R. Crime and Human Nature. New York: Simon and Schuster; 1985.
   Google Scholar
• Gordon MS, Kinlock TW, Couvillion KA, Wilson ME, Schwartz RP, O’Grady KE. Gender differences among prisoners with pre-incarceration heroin dependence participating in a randomized clinical trial of buprenorphine treatment. J Offender Rehabil. 2013;52:376–391.
   PubMedGoogle Scholar
• Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40:500–506.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment (CSAT). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
   Google Scholar
• Kinlock TW, O’Grady KE, Hanlon TE. Prediction of the criminal activity of incarcerated drug-abusing offenders. J Drug Issues. 2003;33:897–920.
   Web of Science ®Google Scholar
• Kinlock TW, Gordon MS. Substance abuse treatment: new research. In: Bennett LA, ed. New Topics in Substance Abuse Treatment. Hauppauge, NY: Nova Science Publishers; 2006:73–111.
   Google Scholar